GENTAUR Molecular Products.
Monoclonal Antibody, ELISA Kit, Polyclonal Antibody, Recombinant/Purified Protein.
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, sales@genprice.com
Index / ListBio / Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4 / Product Detail : 141A Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
Related keywords:
Sep
29th
#141A Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
| Price : | 636 | EUR |
| 722 | USD | |
| 493 | GBP | |
| 2673 | Zloty | |
| 85168 | JPY | |
| 4908 | NOK | |
| 5259 | SEK | |
| 719 | CHF |
Product name : Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
Catalog number : 141A
Quantity: 10µg
Availability: Yes
Supplier name : ListBio
Data sheet: Ask more or other datasheet now !
Contact us about this product :
Our team will respond you as soon as possible !
We have also other products like : Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
Related products : Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
other names
GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
Fax 0032 16 50 90 45
info@gentaur.com | Gentaur
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur
GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50
Fax 01 43 25 01 60
RCS Paris B 484 237 888
SIRET 48423788800017
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
france@gentaur.com | Gentaur
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur
GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel: 0208-080893 Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62 SWIFT RABONL2U
GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur
ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX 058 710 33 48
poland@gentaur.com | Gentaur
Other countries
Österreich +43720880899
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Danmark +4569918806
Finland Helsset +358942419041
Magyarország Budapest +3619980547
Ireland Dublin+35316526556
Luxembourg+35220880274
Norge Oslo+4721031366
Sverige Stockholm+46852503438
Schweiz Züri+41435006251
US New York+17185132983
GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo
Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur
Related products : Botulinum Neurotoxin Type E Nicked from Clostridium botulinum1,3,4
Gentaurpub
WP104: Alanine and aspartate metabolism
WP106: Alanine and aspartate metabolism
WP1126: Tryptophan metabolism
WP1530: miRNA regulation of DNA Damage Response
WP1545: miRNAs involved in DDR
WP2085: miRNAs involved in DDR
WP2087: miRNA regulation of DNA Damage Response
WP2353: vitamin B9 (folate) biosynthesis pathway
WP240: Alanine and aspartate metabolism
WP270: Tryptophan metabolism
WP465: Tryptophan metabolism
WP79: Tryptophan metabolism
WP100: Glutathione metabolism
WP1017: Type II interferon signaling (IFNG)
WP1039: Glutathione metabolism
WP1136: Type II interferon signaling (IFNG)
WP1253: Type II interferon signaling (IFNG)
WP1289: Type II interferon signaling (IFNG)
WP1322: IL-6 Signaling Pathway
WP1329: Alpha6-Beta4 Integrin Signaling Pathway
WP1346: IL-7 Signaling Pathway
WP1348: Androgen Receptor Signaling Pathway
WP1349: Wnt Signaling Pathway
WP1350: Type II interferon signaling (IFNG)
WP1354: B Cell Receptor Signaling Pathway
Related Genes :
[RAC1 TC25 MIG5] Ras-related C3 botulinum toxin substrate 1 (Cell migration-inducing gene 5 protein) (Ras-like protein TC25) (p21-Rac1)
[botA atx bna] Botulinum neurotoxin type A (BoNT/A) (EC 3.4.24.69) (Bontoxilysin-A) (BOTOX) [Cleaved into: Botulinum neurotoxin A light chain; Botulinum neurotoxin A heavy chain]
[Rac1] Ras-related C3 botulinum toxin substrate 1 (p21-Rac1)
[botD] Botulinum neurotoxin type D (BoNT/D) (EC 3.4.24.69) (Bontoxilysin-D) [Cleaved into: Botulinum neurotoxin D light chain; Botulinum neurotoxin D heavy chain]
[botA CBO0806 CLC_0862] Botulinum neurotoxin type A (BoNT/A) (EC 3.4.24.69) (Bontoxilysin-A) (BOTOX) [Cleaved into: Botulinum neurotoxin A light chain; Botulinum neurotoxin A heavy chain]
[] Botulinum neurotoxin type C1 (BoNT/C1) (EC 3.4.24.69) (Bontoxilysin-C1) [Cleaved into: Botulinum neurotoxin C1 light chain; Botulinum neurotoxin C1 heavy chain]
[botB] Botulinum neurotoxin type B (BoNT/B) (EC 3.4.24.69) (Bontoxilysin-B) [Cleaved into: Botulinum neurotoxin B light chain; Botulinum neurotoxin B heavy chain]
[] Botulinum neurotoxin type E (BoNT/E) (EC 3.4.24.69) (Bontoxilysin-E) [Cleaved into: Botulinum neurotoxin E light chain; Botulinum neurotoxin E heavy chain]
[Rac1] Ras-related C3 botulinum toxin substrate 1 (p21-Rac1)
[botF] Botulinum neurotoxin type F (BoNT/F) (EC 3.4.24.69) (Bontoxilysin-F) [Cleaved into: Botulinum neurotoxin F light chain; Botulinum neurotoxin F heavy chain]
[botB CLD_A0068] Botulinum neurotoxin type B (BoNT/B) (EC 3.4.24.69) (Bontoxilysin-B) [Cleaved into: Botulinum neurotoxin B light chain; Botulinum neurotoxin B heavy chain]
[botA atx bna] Botulinum neurotoxin type A (BoNT/A) (EC 3.4.24.69) (Bontoxilysin-A) (BOTOX) [Cleaved into: Botulinum neurotoxin A light chain; Botulinum neurotoxin A heavy chain]
[RAC2] Ras-related C3 botulinum toxin substrate 2 (GX) (Small G protein) (p21-Rac2)
[botG] Botulinum neurotoxin type G (BoNT/G) (EC 3.4.24.69) (Bontoxilysin-G) [Cleaved into: Botulinum neurotoxin G light chain; Botulinum neurotoxin G heavy chain]
[RAC3] Ras-related C3 botulinum toxin substrate 3 (p21-Rac3)
[RAC1 hCG_14926 tcag7.839] Ras-related C3 botulinum toxin substrate 1 (Rho family, small GTP binding protein Rac1) (Ras-related C3 botulinum toxin substrate 1 (Rho family, small GTP binding protein Rac1), isoform CRA_e) (cDNA FLJ77333, highly similar to Homo sapiens ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) (RAC1), transcript variant Rac1b, mRNA)
[Rac2] Ras-related C3 botulinum toxin substrate 2 (Protein EN-7) (p21-Rac2)
[] Botulinum neurotoxin type E (BoNT/E) (EC 3.4.24.69) (Bontoxilysin-E) [Cleaved into: Botulinum neurotoxin E light chain; Botulinum neurotoxin E heavy chain]
[Rac3] Ras-related C3 botulinum toxin substrate 3 (p21-Rac3)
[RAC1] Ras-related C3 botulinum toxin substrate 1
[RAC1] Ras-related C3 botulinum toxin substrate 1
[RAC1] Ras-related C3 botulinum toxin substrate 1
[C3] Mono-ADP-ribosyltransferase C3 (EC 2.4.2.-) (Exoenzyme C3)
[RAC2] Ras-related C3 botulinum toxin substrate 2 (p21-Rac2)
[Rac1 mCG_23557] RAS-related C3 botulinum substrate 1 (RAS-related C3 botulinum substrate 1, isoform CRA_c)
[A bont boNT/A bont/A] Bont/A2 (Botulinum neurotoxin) (Botulinum neurotoxin type A) (Botulinum neurotoxin type A2) (Neurotoxin type A) (Type A2 botulinum neurotoxin)
[a A boNT bont bonta ACP52_06670] BoNT/A (BoNT/A1 neurotoxin) (Bont/A1) (Botulinum neurotoxin type A) (Neurotoxin A) (Neurotoxin BoNT) (Neurotoxin type A) (EC 3.4.24.69) (Peptidase M27)
[RAC1] Ras-related C3 botulinum toxin substrate 1 (p21-Rac1)
[RAC1] Ras-related C3 botulinum toxin substrate 1 (Rac2) (p21-Rac1)
[HA-33 antP-33 ha1] Main hemagglutinin component (HA 33 kDa subunit) (HA1)
Bibliography :
[27677011] Correction of hip internal rotation in walking cerebral palsy adolescent using a soft tissue procedure an alternative to femoral rotation osteotomy.
[27677009] Functional evolution of children cerebral infirm motors (IMC) walking outside the surgery multi-sites: About 47 cases.
[27676990] Hemiplegic shoulder pain: Comparison of two sites of intramuscular injections of botulinum toxin type A, "epautox" study.
[27676974] Botulinum toxin-A for treatment of Pisa syndrome: Towards a decision-making algorithm?
[27676961] Physiological anatomy of botulinum toxin effect on the spastic muscle of children with cerebral palsy.
[27676935] Perceived effectiveness, tolerance of cares in children and adults with cerebral palsy.
[27676911] Therapeutic benefit of botulinum toxin A for the spasticity of the triceps surae in patients with multiple sclerosis: An observational study.
[27676869] Pediatric stroke rehabilitation: A review of techniques facilitating motor recovery.
[27676842] Safety and effectiveness of early intramuscular botulinum toxin injections to prevent shoulder deformity in babies with obstetrical brachial plexus palsy: Presentation of a multicentre randomised double-blind placebo-controlled trial.
[27676841] Pain management in children patient undergoing botulinum toxin injections.
Share this page:
Enter catalog number :
Favorites Pages:
No Favorits